DefiniGEN
Business Services · United Kingdom · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Babraham Research Campus, Cambridge, Cam...Phone Number
+44 1223497123Website
www.definigen.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
1
1
1
1
1
About DefiniGEN
DefiniGEN specializes in iPSC disease modeling services, providing advanced human-derived models for metabolic and rare diseases. Their offerings include efficacy and toxicology screening, gene editing services, and a range of disease models such as MASLD and Wilson's Disease. The company serves a diverse clientele, including top pharmaceutical companies, biotechnology firms, and research institutions, focusing on delivering scalable and predictive liver and metabolic disease models. With over 13 years of experience, DefiniGEN is committed to advancing scientific discoveries through innovative and proprietary iPSC technologies.Explore more
Popular SearchesDEFINIGENDefiniGEN LtdSIC Code 87,873NAICS Code 54,541Show moreSell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is DefiniGEN your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if DefiniGEN is spiking on competitors!
Click to see if DefiniGEN had a recent Job posting/layoffs
Earning: See what the market has to say on DefiniGEN recently announced quarterly report
Product Launch: Get notified when DefiniGEN launches new products
Congratulate Masked Content for being promoted to Masked Content at DefiniGEN
Website visits: Recent activity has been detected on your website
Check if DefiniGEN has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once DefiniGEN has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
DefiniGEN, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined DefiniGEN as Masked Content
Find 2 more new buyers
Compare Similar Companies to DefiniGEN
Compare insights from companies similar to DefiniGEN, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
DefiniGEN
<$5M
11-50
Private
$6.1M
2012
N/A
Company Profile Activity
Activity Insights
DefiniGEN is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
DefiniGEN is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about DefiniGEN.
DefiniGEN financials insights
Gather financial insights about DefiniGEN, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Series A
$3.8M
2016
Private Equity
$2.3M
DefiniGEN Tech Stack
A closer look at the technologies used by DefiniGEN
See more technologies
Most Recent Scoops
Promotion
Executive Move
DefiniGEN has announced that Chris Kirton has been promoted from Chief Operating Officer to the role of Chief Executive Officer.
New Hire
Management Move
Celine Gomez has been named Head of Operations. Previously, Gomez served as Account Manager at Censo Biotechnologies.
Funding
Funding
DefiniGEN News & Media
DefiniGEN appoints Chief Executive Officer - Manufacturing Chemist
Kirton began his operational management career by establishing and growing the cell biology and immunology business unit at a global CRODefiniGEN Secures £3.25 million in Funding to Fast-Track Growth
DefiniGEN – a provider of human cell products and services – has closed a £3.25 million funding round to accelerate its next phase of growth. This includes £2 million from BGF, the UK’s most active investor, alongside its existing consortium of investors led by 24Haymarket.BGF backs DefiniGEN in GBP3.25m funding round
BGF backs DefiniGEN in GBP3.25m funding round Submitted 19/11/2020 - 9:46am DefiniGEN – a provider of human cell products and services – has closed a GBP3.25 million funding round to accelerate its next phase of growth. This includes GBP2 million from BGF, the UK’s most active investor, alongside its existing consortium of investors led by 24Haymarket. DefiniGEN is a spin-out from the University of Cambridge, creating highly predictive disease cell models for preclinical research and
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding DefiniGEN
Sign Up For FreeTo access detailed company insights
DefiniGEN specializes in iPSC disease modeling services, providing advanced human-derived models for metabolic and rare diseases. Their offerings include efficacy and toxicology screening, gene editing services, and a range of disease models such as MASLD and Wilson's Disease. The company serves a diverse clientele, including top pharmaceutical com... Read More
